NIH trial informs potential therapy technique for youths who already tolerate half a peanut or extra.
Monday, February 10, 2025
Consuming progressively rising doses of store-bought, home-measured peanut butter for about 18 months enabled 100% of kids with peanut allergy who initially might tolerate the equal of at the very least half a peanut to devour three tablespoons of peanut butter with out an allergic response, researchers report. This easy-to-implement therapy technique might probably fulfill an unmet want for about half of kids with peanut allergy, who already can tolerate the equal of at the very least half a peanut, thought of a excessive threshold. The findings come from a trial sponsored and funded by the Nationwide Institutes of Well being’s Nationwide Institute of Allergy and Infectious Illnesses (NIAID) and revealed right now within the journal NEJM Proof.
“Kids with high-threshold peanut allergy couldn’t take part in earlier meals allergy therapy trials, leaving them with out alternatives to discover therapy choices,” mentioned NIAID Director Jeanne Marrazzo, M.D., M.P.H. “Right now’s report focuses on this inhabitants and exhibits {that a} very protected and accessible type of remedy could possibly be liberating for a lot of of those kids and their households.”
The meals allergy therapies at present accepted by the Meals and Drug Administration had been examined in kids with low-threshold peanut allergy, who can’t tolerate the equal of even half a peanut. These therapies are designed to lower the probability of a response to a small quantity of peanut regardless of efforts to keep away from it, as would possibly happen with unintended publicity. This method is just not related to the estimated 800,000 U.S. kids who might have high-threshold peanut allergy, leaving them with just one administration technique previous to the brand new report: peanut avoidance.
To handle this want, researchers examined whether or not a low-cost, handy therapy technique might assist kids with high-threshold peanut allergy tolerate a a lot higher quantity of peanut protein than they already did. The mid-stage trial concerned 73 kids ages 4 to 14 years. Based mostly on mum or dad or guardian report, practically 60% of the youngsters had been white, 19% had been Asian, 1.4% had been Black, and 22% had been multiple race. The examine group assigned the youngsters at random to both check the brand new therapy technique or proceed avoiding peanut.
These within the peanut-ingestion group started with a minimal day by day dose of 1/8 teaspoon of peanut butter. They progressively elevated their dose each eight weeks as much as 1 tablespoon of peanut butter or an equal quantity of a special peanut product, reminiscent of peanut flour or candies. Dose will increase came about below medical supervision on the examine web site. Not one of the kids within the peanut-ingestion group wanted epinephrine to deal with extreme allergic reactions throughout house dosing, and just one youngster wanted epinephrine throughout a supervised dosing go to on the examine web site.
After present process the therapy routine, the peanut-consuming kids participated in an oral meals problem rigorously supervised by the examine group to see how a lot peanut butter they might eat with out an allergic response. All 32 kids who participated within the problem might tolerate the utmost quantity of 9 grams of peanut protein, the equal of three tablespoons of peanut butter. In contrast, solely three of the 30 kids within the avoidance group who underwent the oral meals problem after an analogous period of time within the trial might tolerate 9 grams of peanut protein. Three extra kids within the avoidance group tolerated a problem dose at the very least two doses higher than the quantity they might tolerate initially of the examine.
The trial came about through the COVID-19 pandemic, and a few households most well-liked to keep away from indoor shut contact with others at the moment, so some kids didn’t return to the examine web site for the oral meals problem. Utilizing a typical statistical approach to account for these lacking problem outcomes, 100% of the ingestion group and 21% of the avoidance group tolerated at the very least two doses higher than they might on the outset.
Kids within the peanut-ingestion group who might tolerate 9 grams of peanut protein through the oral meals problem consumed at the very least 2 tablespoons of peanut butter weekly for 16 weeks, then prevented peanut totally for eight weeks. At that time, they had been requested to return to the examine web site for a ultimate oral meals problem.
Twenty-six of the 30 handled kids (86.7%) who participated within the ultimate problem continued to tolerate 9 grams of peanut protein, indicating that they had achieved sustained unresponsiveness to peanut. The three kids within the avoidance group who might eat 9 grams of peanut protein with out a response on the earlier problem had been thought of to have developed pure tolerance to peanut. Analyzing these outcomes and together with all 73 kids who started the trial, no matter whether or not they participated within the ultimate problem, investigators discovered that 68.4% of the peanut-ingestion group achieved sustained unresponsiveness, whereas solely 8.6% of the avoidance group developed pure tolerance.
Based mostly on these encouraging outcomes, the investigators wish to be taught if the identical therapy technique would work for meals allergens apart from peanuts. Future follow-up is required to find out the remedy’s effectiveness at inducing long-lasting tolerance of peanut.
Scott H. Sicherer, M.D., and Julie Wang, M.D., led the trial, which came about on the Elliot and Roslyn Jaffe Meals Allergy Institute in Mount Sinai Kravis Kids’s Hospital, New York. Dr. Sicherer is director of the Institute and the Elliot and Roslyn Jaffe Professor of Pediatric Allergy and Immunology. He’s additionally chief of the Division of Allergy and Immunology within the Division of Pediatrics and medical director of the Medical Analysis Unit within the ConduITS Institute for Translational Sciences at Icahn College of Drugs at Mount Sinai. Dr. Wang is a professor of pediatric allergy and immunology within the Elliot and Roslyn Jaffe Meals Allergy Institute.
Extra details about the scientific trial, known as the CAFETERIA examine, is obtainable at ClinicalTrials.gov below examine identifier NCT03907397.
NIAID conducts and helps analysis—at NIH, all through the US, and worldwide—to review the causes of infectious and immune-mediated ailments, and to develop higher technique of stopping, diagnosing and treating these diseases. Information releases, reality sheets and different NIAID-related supplies can be found on the NIAID web site.
Concerning the Nationwide Institutes of Well being (NIH): NIH, the nation’s medical analysis company, contains 27 Institutes and Facilities and is a element of the U.S. Division of Well being and Human Providers. NIH is the first federal company conducting and supporting primary, scientific, and translational medical analysis, and is investigating the causes, therapies, and cures for each frequent and uncommon ailments. For extra details about NIH and its packages, go to www.nih.gov.
NIH…Turning Discovery Into Well being®
Reference
SH Sicherer et al. Randomized trial of excessive dose, house measured peanut oral immunotherapy in kids with excessive threshold peanut allergy. NEJM Proof DOI: 10.1056/EVIDoa2400306(hyperlink is exterior) (2025)
